The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | MRD detection in myeloma autografts: 8-colour flow cytometry or NGS?
Measurable residual disease (MRD) is increasingly being used as a predictor of outcomes in multiple myeloma (MM), which makes its accurate detetction a key step in the management of the disease. Here, Hiroyuki Takamatsu, MD, PhD, of Kanazawa University, Kanazawa, Japan, discusses a study comparing the use of 8-color flow cytometry and next-generation sequencing for the detection of MRD in the autografts of MM patients. This video was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
